Literature DB >> 24618548

Anatomical considerations for the development of a new transcatheter aortopulmonary shunt device in patients with severe pulmonary arterial hypertension.

Kenneth Guo1, David Langleben, Jonathan Afilalo, Avi Shimony, Richard Leask, Ariane Marelli, Giuseppe Martucci, Judith Therrien.   

Abstract

Abstract Morbidity from pulmonary arterial hypertension (PAH) ensues when the pulmonary pressure reaches suprasystemic levels. A transcatheter alternative to the Potts shunt would allow decompression of the right heart without the surgical risks. To aid development of a transcatheter aortopulmonary shunt (TAPS) device, we described the anatomic relationship between the left pulmonary artery (LPA) and the descending aorta (dAO) in adults with severe pulmonary hypertension. Adults with severe PAH (peak systolic pulmonary arterial pressure [PASP] ≥80 mmHg) who had computed tomography of the chest were enrolled. Measurements were taken on the axial plane at the level of the pulmonary artery bifurcation. Forty patients (male sex, 9 patients; median age ± standard deviation [SD], [Formula: see text] years; median PASP ± SD, [Formula: see text] mmHg) were identified. The mean distance (±SD) between the LPA and dAO was [Formula: see text] mm. The mean luminal dAO and LPA diameters (±SD) were [Formula: see text] mm and [Formula: see text] mm, respectively. The LPA and dAO approximated in 93% of patients, with 38% having aortic calcification at the contact site. The mean "landing zone" width and height (defining an area with distance <4 mm between the outer borders) of the two arteries were [Formula: see text] mm and [Formula: see text] mm, respectively, at a mean distance of [Formula: see text] mm from the main pulmonary artery bifurcation. This study shows that the landing zone is able to accommodate a TAPS device of up to 15 mm in diameter in the majority of patients with severe PAH.

Entities:  

Year:  2013        PMID: 24618548      PMCID: PMC4070815          DOI: 10.1086/674328

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  18 in total

1.  Potts shunt in patients with pulmonary hypertension.

Authors:  Julie Blanc; Pascal Vouhé; Damien Bonnet
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

2.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

Authors:  M Humbert; R J Barst; I M Robbins; R N Channick; N Galiè; A Boonstra; L J Rubin; E M Horn; A Manes; G Simonneau
Journal:  Eur Respir J       Date:  2004-09       Impact factor: 16.671

3.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

Authors:  Vallerie V McLaughlin; Ronald J Oudiz; Adaani Frost; Victor F Tapson; Srinivas Murali; Richard N Channick; David B Badesch; Robyn J Barst; Henry H Hsu; Lewis J Rubin
Journal:  Am J Respir Crit Care Med       Date:  2006-08-31       Impact factor: 21.405

4.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results.

Authors:  Alban-Elouen Baruteau; Alain Serraf; Maryline Lévy; Jérôme Petit; Damien Bonnet; Xavier Jais; Pascal Vouhé; Gérald Simonneau; Emre Belli; Marc Humbert
Journal:  Ann Thorac Surg       Date:  2012-06-15       Impact factor: 4.330

6.  Wall motion characteristic of the right pulmonary artery in the suprasternal echocardiogram.

Authors:  W Kasper; T Meinertz; F Kersting; H Löllgen; H Just
Journal:  J Clin Ultrasound       Date:  1980-06       Impact factor: 0.910

7.  Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.

Authors:  W E Hopkins; L L Ochoa; G W Richardson; E P Trulock
Journal:  J Heart Lung Transplant       Date:  1996-01       Impact factor: 10.247

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Authors:  N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

10.  The relationship of pulmonary valve motion to the motion of surrounding cardiac structures: a two-dimensional and dual M-mode echocardiographic study.

Authors:  S E Green; R L Popp
Journal:  Circulation       Date:  1981-07       Impact factor: 29.690

View more
  2 in total

Review 1.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

Review 2.  Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons.

Authors:  Sivasubramanian Ramakrishnan
Journal:  Indian J Pediatr       Date:  2015-07-31       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.